Rheumatic fever primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(7 intermediate revisions by 4 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
Effective measures for the primary prevention of rheumatic fever include reducing exposure to [[group A streptococci]] and antibiotic prophylaxis for [[streptococcal pharyngitis]]. Intramuscular [[benzathine penicillin G]] and oral [[penicillin V]] are the recommended antibiotics in treatment of group A streptococcal infection in absence of [[penicillin allergy]].<ref name="pmid19246689">{{cite journal| author=Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST et al.| title=Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. | journal=Circulation | year= 2009 | volume= 119 | issue= 11 | pages= 1541-51 | pmid=19246689 | doi=10.1161/CIRCULATIONAHA.109.191959 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19246689  }} </ref>
Effective measures for the primary [[prevention]] of rheumatic fever include reducing exposure to [[Group A beta-hemolytic streptococci]] and [[antibiotic]] [[prophylaxis]] for [[streptococcal pharyngitis]]. [[Intramuscular]] [[benzathine penicillin G]] and oral [[penicillin V]] are the recommended [[antibiotics]] in treatment of [[group A streptococcal infection]] in absence of [[penicillin allergy]].


==Primary Prevention==
==Primary Prevention==
Effective measures for the primary prevention of rheumatic fever include reducing exposure to [[group A streptococci]], which requires dramatic improvements in housing, hygiene infrastructure and access to health care for individuals in the developing countries.<ref name="pmid15927077">{{cite journal| author=Robertson KA, Volmink JA, Mayosi BM| title=Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. | journal=BMC Cardiovasc Disord | year= 2005 | volume= 5 | issue= 1 | pages= 11 | pmid=15927077 | doi=10.1186/1471-2261-5-11 | pmc=PMC1164408 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15927077  }} </ref> Most [[streptococcal pharyngitis]], when treated with appropriate antibiotics, prevents acute rheumatic fever.<ref name="pmid15415234">{{cite journal| author=DENNY FW, WANNAMAKER LW, BRINK WR, RAMMELKAMP CH, CUSTER EA| title=Prevention of rheumatic fever; treatment of the preceding streptococcic infection. | journal=J Am Med Assoc | year= 1950 | volume= 143 | issue= 2 | pages= 151-3 | pmid=15415234 | doi= | pmc= | url= }} </ref> Unfortunately, at least one third of episodes of acute rheumatic fever result from unapparent streptococcal infections.<ref name="pmid1945592">{{cite journal| author=Dajani AS| title=Current status of nonsuppurative complications of group A streptococci. | journal=Pediatr Infect Dis J | year= 1991 | volume= 10 | issue= 10 Suppl | pages= S25-7 | pmid=1945592 | doi= | pmc= | url= }} </ref> In addition, some symptomatic patients do not seek medical care; in these instances, rheumatic fever is not preventable.  
Effective measures for the primary [[prevention]] of rheumatic fever include reducing exposure to [[Group A beta-hemolytic streptococci]], which requires dramatic improvements in housing, [[hygiene]] infrastructure and access to health care for individuals in the developing countries.<ref name="pmid15927077">{{cite journal| author=Robertson KA, Volmink JA, Mayosi BM| title=Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. | journal=BMC Cardiovasc Disord | year= 2005 | volume= 5 | issue= 1 | pages= 11 | pmid=15927077 | doi=10.1186/1471-2261-5-11 | pmc=PMC1164408 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15927077  }} </ref> Most [[streptococcal pharyngitis]], when treated with appropriate [[antibiotics]], prevents acute rheumatic fever.<ref name="pmid15415234">{{cite journal| author=DENNY FW, WANNAMAKER LW, BRINK WR, RAMMELKAMP CH, CUSTER EA| title=Prevention of rheumatic fever; treatment of the preceding streptococcic infection. | journal=J Am Med Assoc | year= 1950 | volume= 143 | issue= 2 | pages= 151-3 | pmid=15415234 | doi= | pmc= | url= }} </ref> Unfortunately, at least one third of episodes of acute rheumatic fever result from unapparent [[streptococcal infections]].<ref name="pmid1945592">{{cite journal| author=Dajani AS| title=Current status of nonsuppurative complications of group A streptococci. | journal=Pediatr Infect Dis J | year= 1991 | volume= 10 | issue= 10 Suppl | pages= S25-7 | pmid=1945592 | doi= | pmc= | url= }} </ref> In addition, some [[symptomatic]] [[patients]] do not seek [[medical]] care; in these instances, rheumatic fever is not preventable.  


===Antimicrobial Regimens===
===Antimicrobial Regimens===
*Primary prevention of rheumatic fever via antimicrobial regimens:<ref name="pmid19246689">{{cite journal| author=Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST et al.| title=Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. | journal=Circulation | year= 2009 | volume= 119 | issue= 11 | pages= 1541-51 | pmid=19246689 | doi=10.1161/CIRCULATIONAHA.109.191959 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19246689  }} </ref>
*Primary [[prevention]] of rheumatic fever via [[antimicrobial]] regimens:<ref name="pmid19246689">{{cite journal| author=Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST et al.| title=Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. | journal=Circulation | year= 2009 | volume= 119 | issue= 11 | pages= 1541-51 | pmid=19246689 | doi=10.1161/CIRCULATIONAHA.109.191959 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19246689  }} </ref>
:* Preferred regimen (1): [[Penicillin V]] 500 mg PO q6-8h for 10 days
:* Preferred regimen (1): [[Penicillin V]] 500 mg PO q6-8h for 10 days
:* Preferred regimen (2): [[Amoxicillin]] 50 mg/kg PO qd for 10 days (maximum dose 1 g)
:* Preferred regimen (2): [[Amoxicillin]] 50 mg/kg PO qd for 10 days (maximum dose 1 g)
Line 24: Line 24:


[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Bacterial diseases]]
[[Category:Rheumatology]]
[[Category:Rheumatology]]
[[Category:Primary care]]
[[Category:Disease]]
[[Category: Infectious Disease Project]]
{{WH}}
{{WS}}

Latest revision as of 00:00, 30 July 2020

Rheumatic fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rheumatic Fever from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Jones Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Rheumatic fever primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rheumatic fever primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rheumatic fever primary prevention

CDC on Rheumatic fever primary prevention

Rheumatic fever primary prevention in the news

Blogs on Rheumatic fever primary prevention

Directions to Hospitals Treating Rheumatic fever

Risk calculators and risk factors for Rheumatic fever primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Lance Christiansen, D.O.; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3]; Anthony Gallo, B.S. [4]

Overview

Effective measures for the primary prevention of rheumatic fever include reducing exposure to Group A beta-hemolytic streptococci and antibiotic prophylaxis for streptococcal pharyngitis. Intramuscular benzathine penicillin G and oral penicillin V are the recommended antibiotics in treatment of group A streptococcal infection in absence of penicillin allergy.

Primary Prevention

Effective measures for the primary prevention of rheumatic fever include reducing exposure to Group A beta-hemolytic streptococci, which requires dramatic improvements in housing, hygiene infrastructure and access to health care for individuals in the developing countries.[1] Most streptococcal pharyngitis, when treated with appropriate antibiotics, prevents acute rheumatic fever.[2] Unfortunately, at least one third of episodes of acute rheumatic fever result from unapparent streptococcal infections.[3] In addition, some symptomatic patients do not seek medical care; in these instances, rheumatic fever is not preventable.

Antimicrobial Regimens

  • Preferred regimen (1): Penicillin V 500 mg PO q6-8h for 10 days
  • Preferred regimen (2): Amoxicillin 50 mg/kg PO qd for 10 days (maximum dose 1 g)
  • Preferred regimen (3): Penicillin G 0.6 MU IM single dose (≤27 kg / ≤60 lb); 1.2 MU IM single dose (>27 kg / >60 lb)
  • Alternative regimen (1): Cephalexin 500 mg PO bid for 10 days
  • Alternative regimen (2): Cefadroxil 1 g PO qd for 10 days
  • Alternative regimen (3): Clindamycin 20 mg/kg/day PO tid for 10 days (maximum dose 1.8 g/day)
  • Alternative regimen (4): Azithromycin 12 mg/kg PO qd for 5 days (maximum dose 500 mg/day)
  • Alternative regimen (5): Clarithromycin 15 mg/kg/day PO bid for 10 days (maximum 500 mg/day)

References

  1. Robertson KA, Volmink JA, Mayosi BM (2005). "Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis". BMC Cardiovasc Disord. 5 (1): 11. doi:10.1186/1471-2261-5-11. PMC 1164408. PMID 15927077.
  2. DENNY FW, WANNAMAKER LW, BRINK WR, RAMMELKAMP CH, CUSTER EA (1950). "Prevention of rheumatic fever; treatment of the preceding streptococcic infection". J Am Med Assoc. 143 (2): 151–3. PMID 15415234.
  3. Dajani AS (1991). "Current status of nonsuppurative complications of group A streptococci". Pediatr Infect Dis J. 10 (10 Suppl): S25–7. PMID 1945592.
  4. Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST; et al. (2009). "Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics". Circulation. 119 (11): 1541–51. doi:10.1161/CIRCULATIONAHA.109.191959. PMID 19246689.